Michael Best and Freidrich, LLP, will host a free webinar to discuss new FDA guidelines and their scope of enforcement discretion on medical software applications designed for mobile devices.
Three Vanderbilt technologies received US patent protection in the month of November. One invention includes a compound that targets positive allosteric modulation of the mGlu5 receptor for the treatment of neurological and psychiatric disorders. It was developed at Vanderbilt Center for Neuroscience Drug Discovery which is led by Vanderbilt neuroscientist P.
InvisionHeart, a young Vanderbilt startup, has secured funding and, this week, signed a license agreement with Vanderbilt University regarding the technology that underlies the company’s business.
The week of Dec. 9 - 13 will be a busy one for Vanderbilt innovators and entrepreneurs with talks on entrepreneurial opportunities for physicians, risk reduction in life sciences companies, and a symposium on surgery and engineering.
What if there was a program that connected surgeons, physicians, nursing staff, and other medical care providers with a team of the nation’s top engineers?
Seth Mailhot, J.D., of Michael Best and Friedrich, LLP, visited Vanderbilt University earlier this week and shared understanding of the newly released FDA guidelines on medical software, apps, and devices.
Tuesday, Nov. 19, CTTC will host a special seminar, "When Does a Medical Software/APP Become a Medical Device: Practical Considerations and FDA Guidance”. Leading the seminar will be Seth Mailhot, J.D., attorney at Michael Best and Friedrich, LLP.
They may not have walked away with the million dollar award, but the founders of InvisionHeart gained irreplaceable knowledge and experience from the 2013 Global Food and Health Innovation Challenge.
